Sharon Lynch

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

Robert J. Fox, Christopher S. Coffey, Robin Conwit et al. · New England Journal of Medicine · 2018 · 285 citations · Full text

Medicine, Neurology, Pharmacology +17

Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition

Jared M. Bruce, Laura M. Hancock, Peter A. Arnett et al. · Journal of Behavioral Medicine · 2010 · 280 citations

Social Sciences, Neurology, Psychology +15

Factors that influence adherence with disease-modifying therapy in MS

Katherine Treadaway, Gary Cutter, Amber Salter et al. · Journal of Neurology · 2009 · 257 citations

Pharmacy, Pharmacotherapy, Self-management Support +11

Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern

Dawn C Kroencke, Sharon Lynch, Douglas R. Denney · Multiple Sclerosis Journal · 2000 · 247 citations

Nursing, Neurology, Neuroimmunology +12